Vera Therapeutics announced that its ORIGIN Phase 3 trial of atacicept for IgA nephropathy met its primary endpoint, showing statistically significant and clinically meaningful reductions in ...

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, ...

The Gertrude von Meissner Foundation Research Prize rewards scientific projects in the field of prevention and treatment of disabilities and diseases in children and adolescents.

The APPLAUSE-IgAN results demonstrate that targeted, disease-modifying therapy can preserve long-term kidney function.

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of pat ...

Additionally, EMPAVELI continued to stabilize kidney function as measured by estimated glomerular filtration rate (eGFR), a key measure of kidney function. EMPAVELI showed favorable safety and ...